Observation of clinical efficacy of stereotactic body radiotherapy in 28 cases of large hepatocellular carcinoma
10.3760/cma.j.issn.1004-4221.2019.10.007
- VernacularTitle: 28例大肝癌立体定向放疗疗效观察
- Author:
Jing SUN
1
;
Aimin ZHANG
;
Wengang LI
;
Jia WANG
;
Dan ZHANG
;
Dong LI
;
Junqiang DING
;
Xuezhang DUAN
Author Information
1. Department of Radiation Oncology, Fifth Medical Center of PLA General Hospital (302 Military Hospital), Beijing 100039, China
- Publication Type:Journal Article
- Keywords:
Live neoplasm/stereotactic body radiotherapy;
Prognosis;
Side effect
- From:
Chinese Journal of Radiation Oncology
2019;28(10):749-752
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To observe the survival and side effects of stereotactic body radiotherapy (SBRT) in large hepatocellular carcinoma (HCC) patients.
Methods:Twenty-eight large HCC patients undergoing SBRT in 302 Military Hospital from November 1, 2011 to January 31, 2014 were observed. The prescribed dose was 39-61 Gy/3-9f. Among them, 20 patients simultaneously received transcatheter arterial embolization. The overall survival (OS), progression-free survival (PFS) and local control (LC) rates were calculated by using Kaplan-Meier method. The influencing factors of OS were analyzed by Cox regression model. The influencing factors of radiation-induced liver disease (RILD) were identified by using Logistic regression analysis.
Results:The 1-, 2-, 3-and 5-year OS rates were 75%, 57%, 54% and 22%, respectively. The 1-, 2-, 3-and 5-year PFS rates were 59%, 47%, 36% and 18%, respectively. The 1-, 2-, 3-and 5-year LC rates were 92%, 86%, 86% and 86%, respectively. Four patients suffered from RILD and none died from RILD. Child-Pugh classification was the influencing factor of OS and RILD.
Conclusion:It is preliminarily believed that SBRT is an alternative and safe treatment for patients with large HCC.
